Back to Search
Start Over
323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial
- Source :
- Annals of Oncology. 33:S686
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
- Subjects :
- Oncology
Hematology
Subjects
Details
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology
- Accession number :
- edsair.doi...........040f8d5ab19525c5773f349c828f784d
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.07.461